Ideas

Molecular mechanistic insights into how Local Ice Cryotherapy (LIC) therapy functions as a pain reliever: Mechanistic insights into how Local Ice Cryotherapy (LIC) functions as an analgesic agent: Local Ice Cryotherapy (LIC), used to treat moderate to severe pain, and in others,  increases the expression of PD-L1, decreases the expression of Cox-2, TRPV1, and CGPR, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 27/October/2019, 11.55 pm
Molecular mechanistic insights into how Local Ice Cryotherapy (LIC) therapy functions as a pain reliever: Mechanistic insights into how Local Ice Cryotherapy (LIC) functions as an analgesic agent: Local Ice Cryotherapy (LIC), used to treat moderate to severe pain, and in others,  increases the expression of PD-L1, decreases the expression of Cox-2, TRPV1, and CGPR, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 27/October/2019, 11.55 pm 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for Brain Science, Fudan University, Shanghai,…

read more

Treating advanced cancers resistant to Herceptin and Lapatinib: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancers and in other advanced metastatic cancers resistant to Herceptin and Lapatinib: A pharmaceutical mixture encompassing Dacomitinib  (Trade name: Vizimpro, and PF-00299804)  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2,  p53, and TA-p73/p63, INK4a and others, decreases PP2A and Her2 expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Herceptin and Lapatinib, and stalls advanced breast cancers  progression, and prolongs survival, via up-regulation of its target gene, 21/October/2019, 10.31 pm
Treating advanced cancers resistant to Herceptin and Lapatinib: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancers and in other advanced metastatic cancers resistant to Herceptin and Lapatinib: A pharmaceutical mixture encompassing Dacomitinib  (Trade name: Vizimpro, and PF-00299804)  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2,  p53, and TA-p73/p63, INK4a and others, decreases PP2A and Her2 expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Herceptin and Lapatinib, and stalls advanced breast cancers  progression, and prolongs survival, via up-regulation of its target gene, 21/October/2019, 10.31 pm 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California, USA highlights the role…

read more

Molecular mechanistic insights into how Prasugrel  attenuates pathogenesis-associated with Myocardial infarction and protects against myocardial dysfunction:   Prasugrel (Trade name:  Effient, Efient), a drug used to prevent blood clots, decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target genes, 17/October/2019, 11.29 pm
Molecular mechanistic insights into how Prasugrel  attenuates pathogenesis-associated with Myocardial infarction and protects against myocardial dysfunction:   Prasugrel (Trade name:  Effient, Efient), a drug used to prevent blood clots, decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target genes, 17/October/2019, 11.29 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:  A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

read more

Molecular mechanistic insights into how Magnetic field therapy functions as a pain reliever: Mechanistic insights into how Low-frequency (LF) Pulsed electromagnetic field (PEMF) functions as an analgesic agent: Low-frequency (LF) Pulsed electromagnetic field (PEMF), used to treat moderate to severe pain, and in others,  increases the expression of PD-L1, decreases the expression of Cox-2, TRPV1, and CGPR, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 16/October/2019, 11.34 pm
Molecular mechanistic insights into how Magnetic field therapy functions as a pain reliever: Mechanistic insights into how Low-frequency (LF) Pulsed electromagnetic field (PEMF) functions as an analgesic agent: Low-frequency (LF) Pulsed electromagnetic field (PEMF), used to treat moderate to severe pain, and in others,  increases the expression of PD-L1, decreases the expression of Cox-2, TRPV1, and CGPR, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 16/October/2019, 11.34 pm 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for Brain Science, Fudan University, Shanghai,…

read more

Treating advanced cancers resistant to Herceptin and Lapatinib: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancers and in other advanced metastatic cancers resistant to Herceptin and Lapatinib: A pharmaceutical mixture encompassing Dacomitinib  (Trade name: Vizimpro, and PF-00299804)  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, ACAT1,  p53, and TA-p73/p63, INK4a and others, decreases PP2A and Her2 expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Herceptin and Lapatinib, and stalls advanced breast cancers  progression, and prolongs survival, via up-regulation of its target gene, 13/October/2019, 12.55 am
Treating advanced cancers resistant to Herceptin and Lapatinib: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancers and in other advanced metastatic cancers resistant to Herceptin and Lapatinib: A pharmaceutical mixture encompassing Dacomitinib  (Trade name: Vizimpro, and PF-00299804)  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, ACAT1,  p53, and TA-p73/p63, INK4a and others, decreases PP2A and Her2 expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Herceptin and Lapatinib, and stalls advanced breast cancers  progression, and prolongs survival, via up-regulation of its target gene, 13/October/2019, 12.55 am 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California, USA highlights the role…

read more

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib,  Letrozole  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, ACAT1,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls advanced breast cancer  progression, via up-regulation of its target gene, 5/October/2019, 1.00 am
Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib,  Letrozole  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, ACAT1,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls advanced breast cancer  progression, via up-regulation of its target gene, 5/October/2019, 1.00 am 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica, the…

read more
Start Typing